Ambagon Therapeutics aims to develop first in class protein-protein interaction stabilizer drugs as novel targeted cancer treatments. Ambagon says its approach opens up novel target space as well as having an innovative mechanism of action.
Protein–protein interactions (PPIs) are one of the core processes by which cells function and interact with their environment, making them very interesting targets for modulation by small molecules. There is significant ongoing development of PPI inhibition as a therapeutic strategy. However, Ambagon is taking a new approach and applying its expertise towards PPI stabilization.
Ambagon is initially focused on discovering and developing small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins. Ambagon’s approach selectively augments the endogenous tumor suppression activity of 14-3-3 proteins bound to transcription factors and oncoproteins that have proven challenging to modulate with conventional approaches.
Initially focused on breast cancer, Ambagon says it’s platform approach will also open opportunities to address other major unmet clinical needs.
Subscribe for alerts on new companies featured on Startups.Bio
Aulos Bioscience aims to revolutionize cancer patient care through the development of pioneering Interleukin-2 therapeutics for the treatment of solid tumor cancers. Interleukin-2 or IL-2 …
Code Bio is using its novel targeted non-viral delivery platform to develop genetic medicines for serious and life-threatening diseases such as Type 1 Diabetes and …
Muna Therapeutics aims to preserve brain function and enhance resilience to neurodegenerative diseases. The company engages in the discovery and development of novel therapies that …
Glyphic Biotechnologies is an MIT spin-out aiming to accelerate the critical but slow step of sequencing new proteins, potentially cutting drug development times down by …
ImmuneID is a precision immunology company that has developed a genome-wide, high-throughput platform to provide an understanding of individual immune responses. ImmuneID's aiSPIRE platform screens billions of …
Flare uses a “switch-site based drug discovery approach” to develop a pipeline of therapeutic programs that target pivotal cancer drivers such as transcription factor dysregulation …